Menactra Vaccine

• If you are allergic after a previous dose of a vaccine containing meningococcal capsular polysaccharide, diphtheria toxoid. If you are allergic to any component of Menactra Vaccine.
• If you have a moderate or severe fever or an acute illness, vaccination should be postponed until you have recovered.

• Children Aged 9 to 12 Months: The most frequently reported reactions were tenderness at the injection site and irritability.
• Individuals Aged 2 to 10 Years: The most frequently reported reactions included pain at the injection site and irritability. Diarrhea, drowsiness, and anorexia were also common.
• Adolescents Aged 11 to 18 Years and Adults Aged 18 to 55 Years: The most commonly reported reactions after a single dose were pain at the injection site, headache, fatigue and injection site reactions.
• Booster Vaccination for Ages 15 to 55 Years: The most common reactions were pain at the injection site and muscle pain.

Other General Warnings

• You have kidney disease or have had a kidney transplant.
• You have liver disease or a history of significant liver problems.
• You have ever been diagnosed with Guillain-Barré Syndrome (GBS), as this condition may recur after vaccination.
• You have a bleeding disorder or a low platelet count (thrombocytopenia), as the vaccine is administered intramuscularly and may pose a risk of bleeding.
• You are taking immunosuppressive medication or have a weakened immune system due to illness or treatment, the vaccine may not be as effective for you.
• You have a history of severe allergic reactions to any vaccine or its components.
• You tend to faint easily after injections (fainting or “syncope” has been reported after this vaccine). Precautions should be taken to avoid injury.

• Menactra vaccine is administered as a single 0.5 mL dose via intramuscular injection, preferably in the anterolateral thigh for infants and young children and in the deltoid region for older individuals.
• For children aged 9 to 23 months, a 2-dose series is required, with doses administered at least three months apart. For individuals aged 2 to 55 years: A single dose is sufficient.
• Booster Vaccination (ages 15 to 55 years): A single booster dose may be given if at least 4 years have elapsed since the previous dose and the individual remains at ongoing risk for meningococcal disease.

• Menactra vaccine is recommended for individuals between 9 months and 55 years of age.
• Menactra vaccine helps protect against meningococcal disease caused by serogroups A, C, Y, and W-135, but it does not protect against serogroup B.
• Menactra vaccine is given by intramuscular injection, typically in the thigh for infants and in the upper arm (deltoid muscle) for older children and adults.
• Common side effects include pain, redness, or swelling at the injection site, along with irritability, tiredness, headache, nausea, or diarrhea.
• Serious allergic reactions are rare, but you should seek immediate medical attention if you experience symptoms like swelling, hives, or difficulty breathing.

Overdose

Missed a Dose

How Does It Work?

Interactions with other medicines